FDA Approves Risperdal for Early Onset Bipolar Disorder
On August 22, 2007, the Food and Drug Administration approved Risperdal, a widely used adult psychiatric drug, for the treatment of schizophrenia and bipolar disorder in children and adolescents. The FDA is permitting use of Risperdal for schizophrenia in youths aged 13 to 17, and for bipolar disorder for children and teens ages 10 to 17.
The FDA had not yet approved any drug for the treatment of schizophrenia in children or teens, and only lithium had been approved as a medication for bipolar disorder in adolescents.
